Treatment-Resistant Depression with Anxiety: Augmentation Strategies

Introduction to Augmentation

The American College of Cardiology is not applicable here, however, the most evidence-based add-on strategy is augmentation with an atypical antipsychotic, given that the patient is already on both venlafaxine and mirtazapine—a combination that represents dual-mechanism coverage 1

The current regimen requires optimization, with the venlafaxine dose increased to therapeutic levels (75-225 mg daily) if currently subtherapeutic, as doses below 75 mg are inadequate for treating either depression or anxiety and may paradoxically worsen anxiety symptoms 1

Atypical antipsychotics, such as aripiprazole (2-15 mg) or quetiapine (50-300 mg), added to the current antidepressant regimen represents the strongest augmentation strategy for treatment-resistant depression, with moderate-strength evidence specifically for augmentation in depression that has not responded to adequate antidepressant trials 1
Lithium augmentation is one of the best-documented treatments for treatment-resistant depression, though it requires careful monitoring of blood levels (target 0.6-1.0 mEq/L), thyroid function, and renal function 1
Adding bupropion (150-300 mg SR) to the existing regimen can be considered, particularly if the patient has prominent symptoms of low energy, poor concentration, or psychomotor retardation, however, bupropion is ineffective for PTSD and may not adequately address anxiety symptoms 1, 2

Long-term benzodiazepine use can paradoxically worsen depression and anxiety, create tolerance, and complicate treatment response assessment, according to the American Academy of Sleep Medicine 3

An adequate trial requires a minimum of 4 weeks at therapeutic doses before declaring treatment failure, and treatment duration should be monitored closely 1
Cognitive behavioral therapy shows efficacy comparable to pharmacotherapy in severe depression and may enhance medication response, as supported by the field of Neuropsychopharmacology 4